English

Arch Therapeutics, Inc.

EDGAR

ARTH Quarterly report (10-Q) · filed 2024-08-19

67 filing records in this dataset, filed from 2012-01-05 to 2024-08-19. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

30.9 thousand USD

2024 Q3 · USD

Exact inputs and evidence

Revenue: 30913 USD Source

Operating margin

-3,304.36%

2024 Q3 · %

Exact inputs and evidence

Operating Income: -1021476 USD Source
Revenue: 30913 USD Source

Operating cash flow

-912 thousand USD

2024 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -2474405 USD Source
Operating Cash Flow: -1562764 USD Source

Cash and cash equivalents: 1.96 million USD 2019-03-31 Source
Exact value

1956260 USD
Long-term debt including current maturities: Not available
Shares outstanding: 4.44 million shares 2024-06-30 Source
Exact value

4444364 shares

Reported share-count change

245.81% · 3.16 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

1285213 shares · 2023-06-30· Source
4444364 shares · 2024-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-08-19.

Financial data available through: 2023-09-30.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2023-09-30
Operating income: 10 of 11 periods available· newest 2023-09-30
Net income: 10 of 11 periods available· newest 2023-09-30
Operating cash flow: 10 of 11 periods available· newest 2023-09-30
Capital expenditure: 8 of 11 periods available· newest 2023-09-30
Total assets: 10 of 11 periods available· newest 2023-09-30
Total liabilities: 10 of 11 periods available· newest 2023-09-30
Current assets: 10 of 11 periods available· newest 2023-09-30
Current liabilities: 10 of 11 periods available· newest 2023-09-30
Cash and cash equivalents: 6 of 11 periods available· newest 2018-09-30
Long-term debt including current maturities: Multiple units; comparison withheld· newest 2021-09-30
Shares outstanding: 10 of 11 periods available· newest 2023-09-30

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+383.8%

Prior period

USD 15,652

2021-10-01 – 2022-09-30
Current period

USD 75,724

2022-10-01 – 2023-09-30

Exact inputs and evidence

75724 − 15652 = 60072 USD

15652 USD · 2021-10-01 – 2022-09-30
Inspect prior input Prior source
75724 USD · 2022-10-01 – 2023-09-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Arch Therapeutics, Inc. · 2023-09-30 Arch Therapeutics, Inc. (edgar:1537561) Year-over-year change in Revenue: 60072 USD Concept: fundies:Revenue Period: 2022-10-01 to 2023-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 75724 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#1920764 Filing: 000143774924004234 Input fundies:Revenue: 15652 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#1921391 Filing: 000143774924004234
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 1.71 million

Prior period

−USD 5.28 million

2021-10-01 – 2022-09-30
Current period

−USD 6.98 million

2022-10-01 – 2023-09-30

Exact inputs and evidence

-6982836 − -5275854 = -1706982 USD

-5275854 USD · 2021-10-01 – 2022-09-30
Inspect prior input Prior source
-6982836 USD · 2022-10-01 – 2023-09-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Arch Therapeutics, Inc. · 2023-09-30 Arch Therapeutics, Inc. (edgar:1537561) Year-over-year change in Net income: -1706982 USD Concept: fundies:NetIncome Period: 2022-10-01 to 2023-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -6982836 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2129531 Filing: 000143774924004234 Input fundies:NetIncome: -5275854 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2059214 Filing: 000143774924004234
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 1.08 million

Prior period

−USD 4.46 million

2021-10-01 – 2022-09-30
Current period

−USD 3.37 million

2022-10-01 – 2023-09-30

Exact inputs and evidence

-3374216 − -4456075 = 1081859 USD

-4456075 USD · 2021-10-01 – 2022-09-30
Inspect prior input Prior source
-3374216 USD · 2022-10-01 – 2023-09-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Arch Therapeutics, Inc. · 2023-09-30 Arch Therapeutics, Inc. (edgar:1537561) Year-over-year change in Operating cash flow: 1081859 USD Concept: fundies:OperatingCashFlow Period: 2022-10-01 to 2023-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -3374216 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2129757 Filing: 000143774924004234 Input fundies:OperatingCashFlow: -4456075 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2081495 Filing: 000143774924004234
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+USD 4,521

Prior period

USD 0

2021-10-01 – 2022-09-30
Current period

USD 4,521

2022-10-01 – 2023-09-30

Exact inputs and evidence

4521 − -0 = 4521 USD

-0 USD · 2021-10-01 – 2022-09-30
Inspect prior input Prior source
4521 USD · 2022-10-01 – 2023-09-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Arch Therapeutics, Inc. · 2023-09-30 Arch Therapeutics, Inc. (edgar:1537561) Year-over-year change in Capital expenditure: 4521 USD Concept: fundies:CapitalExpenditure Period: 2022-10-01 to 2023-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 4521 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2083940 Filing: 000143774924004234 Input fundies:CapitalExpenditure: -0 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2084779 Filing: 000143774924004234
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2022-10-01 – 2023-09-30

Revenue USD 75,724 100% of revenue
Cost of revenue USD 78,163 103% of revenue
Operating expenses USD 5.04 million 6,658% of revenue
Operating income −USD 5.04 million −6,662% of revenue
Tax, interest and other Derived USD 1.94 million 2,560% of revenue
Net income −USD 6.98 million −9,221% of revenue

Cash

Operating cash flow −USD 3.37 million −4,456% of revenue
Capital expenditure USD 4,521 6% of revenue
Free cash flow Derived −USD 3.38 million −4,462% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2013 Not shown: operating income or net income is not reported.
2014 Not shown: operating income or net income is not reported.
2015 Not shown: operating income or net income is not reported.
2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.
2021 Operating loss: operating costs were 55,242% of revenue.
2022 Operating loss: operating costs were 36,573% of revenue.
2023 Operating loss: operating costs were 6,762% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2013 2012-10-01 – 2013-09-30	0	1744976 Derived	-1744976	108815 Derived	-1853791	-1434620 Derived	Source 2012-10-01 – 2013-09-30: 0 USD Inspect Revenue Open source 2012-10-01 – 2013-09-30: -1744976 USD Inspect Operating Income Open source 2012-10-01 – 2013-09-30: -1853791 USD Inspect Net Income Open source 2012-10-01 – 2013-09-30: -1434620 USD Inspect Operating Cash Flow Open source 2012-10-01 – 2013-09-30: 0 USD Inspect Capital Expenditure Open source
2014 2013-10-01 – 2014-09-30	0	4611764 Derived	-4611764	3531059 Derived	-8142823	Unavailable	Source 2013-10-01 – 2014-09-30: 0 USD Inspect Revenue Open source 2013-10-01 – 2014-09-30: -4611764 USD Inspect Operating Income Open source 2013-10-01 – 2014-09-30: -8142823 USD Inspect Net Income Open source 2013-10-01 – 2014-09-30: -3348502 USD Inspect Operating Cash Flow Open source
2015 2014-10-01 – 2015-09-30	0	5460514 Derived	-5460514	-2512988 Derived	-2947526	Unavailable	Source 2014-10-01 – 2015-09-30: 0 USD Inspect Revenue Open source 2014-10-01 – 2015-09-30: -5460514 USD Inspect Operating Income Open source 2014-10-01 – 2015-09-30: -2947526 USD Inspect Net Income Open source 2014-10-01 – 2015-09-30: -4239386 USD Inspect Operating Cash Flow Open source
2016 2015-10-01 – 2016-09-30	0	6050775 Derived	-6050775	-58405 Derived	-5992370	-4747027 Derived	Source 2015-10-01 – 2016-09-30: 0 USD Inspect Revenue Open source 2015-10-01 – 2016-09-30: -6050775 USD Inspect Operating Income Open source 2015-10-01 – 2016-09-30: -5992370 USD Inspect Net Income Open source 2015-10-01 – 2016-09-30: -4747027 USD Inspect Operating Cash Flow Open source 2015-10-01 – 2016-09-30: 0 USD Inspect Capital Expenditure Open source
2017 2016-10-01 – 2017-09-30	0	7302548 Derived	-7302548	486308 Derived	-7788856	-5624934 Derived	Source 2016-10-01 – 2017-09-30: 0 USD Inspect Revenue Open source 2016-10-01 – 2017-09-30: -7302548 USD Inspect Operating Income Open source 2016-10-01 – 2017-09-30: -7788856 USD Inspect Net Income Open source 2016-10-01 – 2017-09-30: -5616248 USD Inspect Operating Cash Flow Open source 2016-10-01 – 2017-09-30: 8686 USD Inspect Capital Expenditure Open source
2018 2017-10-01 – 2018-09-30	0	7449767 Derived	-7449767	-2635735 Derived	-4814032	-5928978 Derived	Source 2017-10-01 – 2018-09-30: 0 USD Inspect Revenue Open source 2017-10-01 – 2018-09-30: -7449767 USD Inspect Operating Income Open source 2017-10-01 – 2018-09-30: -4814032 USD Inspect Net Income Open source 2017-10-01 – 2018-09-30: -5913563 USD Inspect Operating Cash Flow Open source 2017-10-01 – 2018-09-30: 15415 USD Inspect Capital Expenditure Open source
2020 2019-10-01 – 2020-09-30	0	5352114 Derived	-5352114	-660737 Derived	-4691377	-5047210 Derived	Source 2019-10-01 – 2020-09-30: 0 USD Inspect Revenue Open source 2019-10-01 – 2020-09-30: -5352114 USD Inspect Operating Income Open source 2019-10-01 – 2020-09-30: -4691377 USD Inspect Net Income Open source 2019-10-01 – 2020-09-30: -5044755 USD Inspect Operating Cash Flow Open source 2019-10-01 – 2020-09-30: 2455 USD Inspect Capital Expenditure Open source
2021 2020-10-01 – 2021-09-30	11565	6388689 Derived	-6377124	-136642 Derived	-6240482	-5961903 Derived	Source 2020-10-01 – 2021-09-30: 11565 USD Inspect Revenue Open source 2020-10-01 – 2021-09-30: -6377124 USD Inspect Operating Income Open source 2020-10-01 – 2021-09-30: -6240482 USD Inspect Net Income Open source 2020-10-01 – 2021-09-30: -5958628 USD Inspect Operating Cash Flow Open source 2020-10-01 – 2021-09-30: 3275 USD Inspect Capital Expenditure Open source
2022 2021-10-01 – 2022-09-30	15652	5724458 Derived	-5708806	-432952 Derived	-5275854	-4456075 Derived	Source 2021-10-01 – 2022-09-30: 15652 USD Inspect Revenue Open source 2021-10-01 – 2022-09-30: -5708806 USD Inspect Operating Income Open source 2021-10-01 – 2022-09-30: -5275854 USD Inspect Net Income Open source 2021-10-01 – 2022-09-30: -4456075 USD Inspect Operating Cash Flow Open source 2021-10-01 – 2022-09-30: -0 USD Inspect Capital Expenditure Open source
2023 2022-10-01 – 2023-09-30	75724	5120207 Derived	-5044483	1938353 Derived	-6982836	-3378737 Derived	Source 2022-10-01 – 2023-09-30: 75724 USD Inspect Revenue Open source 2022-10-01 – 2023-09-30: -5044483 USD Inspect Operating Income Open source 2022-10-01 – 2023-09-30: -6982836 USD Inspect Net Income Open source 2022-10-01 – 2023-09-30: -3374216 USD Inspect Operating Cash Flow Open source 2022-10-01 – 2023-09-30: 4521 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 75.7K 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-09-30	Revenue	0	Revenue: 0 Open source
20142014-09-30	Revenue	0	Revenue: 0 Open source
20152015-09-30	Revenue	0	Revenue: 0 Open source
20162016-09-30	Revenue	0	Revenue: 0 Open source
20172017-09-30	Revenue	0	Revenue: 0 Open source
20182018-09-30	Revenue	0	Revenue: 0 Open source
20202020-09-30	Revenue	0	Revenue: 0 Open source
20212021-09-30	Revenue	11565	Revenue: 11565 Open source
20222022-09-30	Revenue	15652	Revenue: 15652 Open source
20232023-09-30	Revenue	75724	Revenue: 75724 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

383.8% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20132013-09-30	Year over year	No prior comparable period	Revenue: 0 Open source
20142014-09-30	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20152015-09-30	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20162016-09-30	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20172017-09-30	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20182018-09-30	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20202020-09-30	Year over year	No prior comparable period	Revenue: 0 Open source
20212021-09-30	Year over year	No prior comparable period	Revenue: 11565 Open source Revenue: 0 Open source
20222022-09-30	Year over year	35.3%	Revenue: 15652 Open source Revenue: 11565 Open source
20232023-09-30	Year over year	383.8%	Revenue: 75724 Open source Revenue: 15652 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -6,661.7% 2023

Net margin -9,221.4% 2023

Free cash flow margin -4,461.9% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20132013-09-30	Operating margin	Not reported	Operating Income: -1744976 Open source Revenue: 0 Open source
20142014-09-30	Operating margin	Not reported	Operating Income: -4611764 Open source Revenue: 0 Open source
20152015-09-30	Operating margin	Not reported	Operating Income: -5460514 Open source Revenue: 0 Open source
20162016-09-30	Operating margin	Not reported	Operating Income: -6050775 Open source Revenue: 0 Open source
20172017-09-30	Operating margin	Not reported	Operating Income: -7302548 Open source Revenue: 0 Open source
20182018-09-30	Operating margin	Not reported	Operating Income: -7449767 Open source Revenue: 0 Open source
20202020-09-30	Operating margin	Not reported	Operating Income: -5352114 Open source Revenue: 0 Open source
20212021-09-30	Operating margin	-55,141.6%	Operating Income: -6377124 Open source Revenue: 11565 Open source
20222022-09-30	Operating margin	-36,473.3%	Operating Income: -5708806 Open source Revenue: 15652 Open source
20232023-09-30	Operating margin	-6,661.7%	Operating Income: -5044483 Open source Revenue: 75724 Open source
20132013-09-30	Net margin	Not reported	Net Income: -1853791 Open source Revenue: 0 Open source
20142014-09-30	Net margin	Not reported	Net Income: -8142823 Open source Revenue: 0 Open source
20152015-09-30	Net margin	Not reported	Net Income: -2947526 Open source Revenue: 0 Open source
20162016-09-30	Net margin	Not reported	Net Income: -5992370 Open source Revenue: 0 Open source
20172017-09-30	Net margin	Not reported	Net Income: -7788856 Open source Revenue: 0 Open source
20182018-09-30	Net margin	Not reported	Net Income: -4814032 Open source Revenue: 0 Open source
20202020-09-30	Net margin	Not reported	Net Income: -4691377 Open source Revenue: 0 Open source
20212021-09-30	Net margin	-53,960.1%	Net Income: -6240482 Open source Revenue: 11565 Open source
20222022-09-30	Net margin	-33,707.2%	Net Income: -5275854 Open source Revenue: 15652 Open source
20232023-09-30	Net margin	-9,221.4%	Net Income: -6982836 Open source Revenue: 75724 Open source
20132013-09-30	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -1434620 Open source Capital Expenditure: 0 Open source
20142014-09-30	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -3348502 Open source
20152015-09-30	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -4239386 Open source
20162016-09-30	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -4747027 Open source Capital Expenditure: 0 Open source
20172017-09-30	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -5616248 Open source Capital Expenditure: 8686 Open source
20182018-09-30	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -5913563 Open source Capital Expenditure: 15415 Open source
20202020-09-30	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -5044755 Open source Capital Expenditure: 2455 Open source
20212021-09-30	Free cash flow margin	-51,551.3%	Revenue: 11565 Open source Operating Cash Flow: -5958628 Open source Capital Expenditure: 3275 Open source
20222022-09-30	Free cash flow margin	-28,469.7%	Revenue: 15652 Open source Operating Cash Flow: -4456075 Open source Capital Expenditure: -0 Open source
20232023-09-30	Free cash flow margin	-4,461.9%	Revenue: 75724 Open source Operating Cash Flow: -3374216 Open source Capital Expenditure: 4521 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -3.4M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-09-30	Operating cash flow	-1434620	Operating Cash Flow: -1434620 Open source
20142014-09-30	Operating cash flow	-3348502	Operating Cash Flow: -3348502 Open source
20152015-09-30	Operating cash flow	-4239386	Operating Cash Flow: -4239386 Open source
20162016-09-30	Operating cash flow	-4747027	Operating Cash Flow: -4747027 Open source
20172017-09-30	Operating cash flow	-5616248	Operating Cash Flow: -5616248 Open source
20182018-09-30	Operating cash flow	-5913563	Operating Cash Flow: -5913563 Open source
20202020-09-30	Operating cash flow	-5044755	Operating Cash Flow: -5044755 Open source
20212021-09-30	Operating cash flow	-5958628	Operating Cash Flow: -5958628 Open source
20222022-09-30	Operating cash flow	-4456075	Operating Cash Flow: -4456075 Open source
20232023-09-30	Operating cash flow	-3374216	Operating Cash Flow: -3374216 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -3.4M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-09-30	Free cash flow	-1434620	Operating Cash Flow: -1434620 Open source Capital Expenditure: 0 Open source
20142014-09-30	Free cash flow	Unavailable	Operating Cash Flow: -3348502 Open source
20152015-09-30	Free cash flow	Unavailable	Operating Cash Flow: -4239386 Open source
20162016-09-30	Free cash flow	-4747027	Operating Cash Flow: -4747027 Open source Capital Expenditure: 0 Open source
20172017-09-30	Free cash flow	-5624934	Operating Cash Flow: -5616248 Open source Capital Expenditure: 8686 Open source
20182018-09-30	Free cash flow	-5928978	Operating Cash Flow: -5913563 Open source Capital Expenditure: 15415 Open source
20202020-09-30	Free cash flow	-5047210	Operating Cash Flow: -5044755 Open source Capital Expenditure: 2455 Open source
20212021-09-30	Free cash flow	-5961903	Operating Cash Flow: -5958628 Open source Capital Expenditure: 3275 Open source
20222022-09-30	Free cash flow	-4456075	Operating Cash Flow: -4456075 Open source Capital Expenditure: -0 Open source
20232023-09-30	Free cash flow	-3378737	Operating Cash Flow: -3374216 Open source Capital Expenditure: 4521 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

483.4% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20132013-09-30	Liabilities / assets	88.2%	Total Liabilities: 1400316 Open source Total Assets: 1587332 Open source
20142014-09-30	Liabilities / assets	885.9%	Total Liabilities: 7769433 Open source Total Assets: 876990 Open source
20152015-09-30	Liabilities / assets	61.5%	Total Liabilities: 2462902 Open source Total Assets: 4003019 Open source
20162016-09-30	Liabilities / assets	38.6%	Total Liabilities: 1983265 Open source Total Assets: 5144260 Open source
20172017-09-30	Liabilities / assets	63.4%	Total Liabilities: 3863564 Open source Total Assets: 6090083 Open source
20182018-09-30	Liabilities / assets	71.9%	Total Liabilities: 3480137 Open source Total Assets: 4839965 Open source
20202020-09-30	Liabilities / assets	169.8%	Total Liabilities: 3651518 Open source Total Assets: 2151027 Open source
20212021-09-30	Liabilities / assets	127.9%	Total Liabilities: 4702159 Open source Total Assets: 3676485 Open source
20222022-09-30	Liabilities / assets	261%	Total Liabilities: 6796542 Open source Total Assets: 2603739 Open source
20232023-09-30	Liabilities / assets	483.4%	Total Liabilities: 9465921 Open source Total Assets: 1958189 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.21× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20132013-09-30	Current assets / current liabilities	3.46×	Current Assets: 1576948 Open source Current Liabilities: 455609 Open source
20142014-09-30	Current assets / current liabilities	0.32×	Current Assets: 876990 Open source Current Liabilities: 2723667 Open source
20152015-09-30	Current assets / current liabilities	3.11×	Current Assets: 4003019 Open source Current Liabilities: 1286078 Open source
20162016-09-30	Current assets / current liabilities	2.74×	Current Assets: 5144260 Open source Current Liabilities: 1878780 Open source
20172017-09-30	Current assets / current liabilities	14.02×	Current Assets: 6079395 Open source Current Liabilities: 433531 Open source
20182018-09-30	Current assets / current liabilities	16.71×	Current Assets: 4819204 Open source Current Liabilities: 288385 Open source
20202020-09-30	Current assets / current liabilities	3.41×	Current Assets: 2142975 Open source Current Liabilities: 628460 Open source
20212021-09-30	Current assets / current liabilities	2.12×	Current Assets: 3667745 Open source Current Liabilities: 1727547 Open source
20222022-09-30	Current assets / current liabilities	0.78×	Current Assets: 2598195 Open source Current Liabilities: 3320494 Open source
20232023-09-30	Current assets / current liabilities	0.21×	Current Assets: 1950090 Open source Current Liabilities: 9465921 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2013 2012-10-01 – 2013-09-30	−USD 1.85 million Exact value Exact value: -1853791 USD 2012-10-01 – 2013-09-30: -1853791 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arch Therapeutics, Inc. · 2013-09-30 Arch Therapeutics, Inc. (edgar:1537561) Net Income: -1853791 USD Concept: fundies:NetIncome Period: 2012-10-01 to 2013-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ANetIncome&period=2013-09-30&surface=latest&period_type=duration&start=2012-10-01&unit=USD&dimensions= Input fundies:NetIncome: -1853791 USD (2012-10-01 to 2013-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420415054527/arth-20150630.xml#709027 Filing: 000114420415054527 The citation records this snapshot. The page link may show a newer release later.	−USD 1.43 million Exact value Exact value: -1434620 USD 2012-10-01 – 2013-09-30: -1434620 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arch Therapeutics, Inc. · 2013-09-30 Arch Therapeutics, Inc. (edgar:1537561) Operating Cash Flow: -1434620 USD Concept: fundies:OperatingCashFlow Period: 2012-10-01 to 2013-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3AOperatingCashFlow&period=2013-09-30&surface=latest&period_type=duration&start=2012-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1434620 USD (2012-10-01 to 2013-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420415054527/arth-20150630.xml#866296 Filing: 000114420415054527 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2012-10-01 – 2013-09-30: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arch Therapeutics, Inc. · 2013-09-30 Arch Therapeutics, Inc. (edgar:1537561) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2012-10-01 to 2013-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ACapitalExpenditure&period=2013-09-30&surface=latest&period_type=duration&start=2012-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2012-10-01 to 2013-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420414026915/arth-20130930.xml#125948 Filing: 000114420414026915 The citation records this snapshot. The page link may show a newer release later.	−USD 1.43 million Calculation and evidence -1434620 − 0 USD Exact free cash flow: -1434620 USD 2012-10-01 – 2013-09-30: -1434620 USD · Inspect Operating Cash Flow · Source 2012-10-01 – 2013-09-30: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arch Therapeutics, Inc. · 2013-09-30 Arch Therapeutics, Inc. (edgar:1537561) Free cash flow: -1434620 USD Concept: free-cash-flow Period: 2012-10-01 to 2013-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1434620 USD (2012-10-01 to 2013-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420415054527/arth-20150630.xml#866296 Filing: 000114420415054527 Input fundies:CapitalExpenditure: 0 USD (2012-10-01 to 2013-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420414026915/arth-20130930.xml#125948 Filing: 000114420414026915 The citation records this snapshot. The page link may show a newer release later.
2014 2013-10-01 – 2014-09-30	−USD 8.14 million Exact value Exact value: -8142823 USD 2013-10-01 – 2014-09-30: -8142823 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arch Therapeutics, Inc. · 2014-09-30 Arch Therapeutics, Inc. (edgar:1537561) Net Income: -8142823 USD Concept: fundies:NetIncome Period: 2013-10-01 to 2014-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ANetIncome&period=2014-09-30&surface=latest&period_type=duration&start=2013-10-01&unit=USD&dimensions= Input fundies:NetIncome: -8142823 USD (2013-10-01 to 2014-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420416109625/arth-20160331.xml#174649 Filing: 000114420416109625 The citation records this snapshot. The page link may show a newer release later.	−USD 3.35 million Exact value Exact value: -3348502 USD 2013-10-01 – 2014-09-30: -3348502 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arch Therapeutics, Inc. · 2014-09-30 Arch Therapeutics, Inc. (edgar:1537561) Operating Cash Flow: -3348502 USD Concept: fundies:OperatingCashFlow Period: 2013-10-01 to 2014-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3AOperatingCashFlow&period=2014-09-30&surface=latest&period_type=duration&start=2013-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3348502 USD (2013-10-01 to 2014-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420416109625/arth-20160331.xml#178266 Filing: 000114420416109625 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2015 2014-10-01 – 2015-09-30	−USD 2.95 million Exact value Exact value: -2947526 USD 2014-10-01 – 2015-09-30: -2947526 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arch Therapeutics, Inc. · 2015-09-30 Arch Therapeutics, Inc. (edgar:1537561) Net Income: -2947526 USD Concept: fundies:NetIncome Period: 2014-10-01 to 2015-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ANetIncome&period=2015-09-30&surface=latest&period_type=duration&start=2014-10-01&unit=USD&dimensions= Input fundies:NetIncome: -2947526 USD (2014-10-01 to 2015-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420416137852/arth-20160930.xml#149043 Filing: 000114420416137852 The citation records this snapshot. The page link may show a newer release later.	−USD 4.24 million Exact value Exact value: -4239386 USD 2014-10-01 – 2015-09-30: -4239386 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arch Therapeutics, Inc. · 2015-09-30 Arch Therapeutics, Inc. (edgar:1537561) Operating Cash Flow: -4239386 USD Concept: fundies:OperatingCashFlow Period: 2014-10-01 to 2015-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3AOperatingCashFlow&period=2015-09-30&surface=latest&period_type=duration&start=2014-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4239386 USD (2014-10-01 to 2015-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420416137852/arth-20160930.xml#152053 Filing: 000114420416137852 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2016 2015-10-01 – 2016-09-30	−USD 5.99 million Exact value Exact value: -5992370 USD 2015-10-01 – 2016-09-30: -5992370 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arch Therapeutics, Inc. · 2016-09-30 Arch Therapeutics, Inc. (edgar:1537561) Net Income: -5992370 USD Concept: fundies:NetIncome Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ANetIncome&period=2016-09-30&surface=latest&period_type=duration&start=2015-10-01&unit=USD&dimensions= Input fundies:NetIncome: -5992370 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420417059213/arth-20170930.xml#124482 Filing: 000114420417059213 The citation records this snapshot. The page link may show a newer release later.	−USD 4.75 million Exact value Exact value: -4747027 USD 2015-10-01 – 2016-09-30: -4747027 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arch Therapeutics, Inc. · 2016-09-30 Arch Therapeutics, Inc. (edgar:1537561) Operating Cash Flow: -4747027 USD Concept: fundies:OperatingCashFlow Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3AOperatingCashFlow&period=2016-09-30&surface=latest&period_type=duration&start=2015-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4747027 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420417059213/arth-20170930.xml#142882 Filing: 000114420417059213 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2015-10-01 – 2016-09-30: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arch Therapeutics, Inc. · 2016-09-30 Arch Therapeutics, Inc. (edgar:1537561) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ACapitalExpenditure&period=2016-09-30&surface=latest&period_type=duration&start=2015-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420417059213/arth-20170930.xml#447554 Filing: 000114420417059213 The citation records this snapshot. The page link may show a newer release later.	−USD 4.75 million Calculation and evidence -4747027 − 0 USD Exact free cash flow: -4747027 USD 2015-10-01 – 2016-09-30: -4747027 USD · Inspect Operating Cash Flow · Source 2015-10-01 – 2016-09-30: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arch Therapeutics, Inc. · 2016-09-30 Arch Therapeutics, Inc. (edgar:1537561) Free cash flow: -4747027 USD Concept: free-cash-flow Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4747027 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420417059213/arth-20170930.xml#142882 Filing: 000114420417059213 Input fundies:CapitalExpenditure: 0 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420417059213/arth-20170930.xml#447554 Filing: 000114420417059213 The citation records this snapshot. The page link may show a newer release later.
2017 2016-10-01 – 2017-09-30	−USD 7.79 million Exact value Exact value: -7788856 USD 2016-10-01 – 2017-09-30: -7788856 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arch Therapeutics, Inc. · 2017-09-30 Arch Therapeutics, Inc. (edgar:1537561) Net Income: -7788856 USD Concept: fundies:NetIncome Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ANetIncome&period=2017-09-30&surface=latest&period_type=duration&start=2016-10-01&unit=USD&dimensions= Input fundies:NetIncome: -7788856 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420418065134/arth-20180930.xml#1223292 Filing: 000114420418065134 The citation records this snapshot. The page link may show a newer release later.	−USD 5.62 million Exact value Exact value: -5616248 USD 2016-10-01 – 2017-09-30: -5616248 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arch Therapeutics, Inc. · 2017-09-30 Arch Therapeutics, Inc. (edgar:1537561) Operating Cash Flow: -5616248 USD Concept: fundies:OperatingCashFlow Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3AOperatingCashFlow&period=2017-09-30&surface=latest&period_type=duration&start=2016-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5616248 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420418065134/arth-20180930.xml#1222169 Filing: 000114420418065134 The citation records this snapshot. The page link may show a newer release later.	USD 8,686 Exact value Exact value: 8686 USD 2016-10-01 – 2017-09-30: 8686 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arch Therapeutics, Inc. · 2017-09-30 Arch Therapeutics, Inc. (edgar:1537561) Capital Expenditure: 8686 USD Concept: fundies:CapitalExpenditure Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ACapitalExpenditure&period=2017-09-30&surface=latest&period_type=duration&start=2016-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8686 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420418065134/arth-20180930.xml#1227300 Filing: 000114420418065134 The citation records this snapshot. The page link may show a newer release later.	−USD 5.62 million Calculation and evidence -5616248 − 8686 USD Exact free cash flow: -5624934 USD 2016-10-01 – 2017-09-30: -5616248 USD · Inspect Operating Cash Flow · Source 2016-10-01 – 2017-09-30: 8686 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arch Therapeutics, Inc. · 2017-09-30 Arch Therapeutics, Inc. (edgar:1537561) Free cash flow: -5624934 USD Concept: free-cash-flow Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5616248 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420418065134/arth-20180930.xml#1222169 Filing: 000114420418065134 Input fundies:CapitalExpenditure: 8686 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420418065134/arth-20180930.xml#1227300 Filing: 000114420418065134 The citation records this snapshot. The page link may show a newer release later.
2018 2017-10-01 – 2018-09-30	−USD 4.81 million Exact value Exact value: -4814032 USD 2017-10-01 – 2018-09-30: -4814032 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arch Therapeutics, Inc. · 2018-09-30 Arch Therapeutics, Inc. (edgar:1537561) Net Income: -4814032 USD Concept: fundies:NetIncome Period: 2017-10-01 to 2018-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ANetIncome&period=2018-09-30&surface=latest&period_type=duration&start=2017-10-01&unit=USD&dimensions= Input fundies:NetIncome: -4814032 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420418065134/arth-20180930.xml#1223152 Filing: 000114420418065134 The citation records this snapshot. The page link may show a newer release later.	−USD 5.91 million Exact value Exact value: -5913563 USD 2017-10-01 – 2018-09-30: -5913563 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arch Therapeutics, Inc. · 2018-09-30 Arch Therapeutics, Inc. (edgar:1537561) Operating Cash Flow: -5913563 USD Concept: fundies:OperatingCashFlow Period: 2017-10-01 to 2018-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3AOperatingCashFlow&period=2018-09-30&surface=latest&period_type=duration&start=2017-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5913563 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420418065134/arth-20180930.xml#1221971 Filing: 000114420418065134 The citation records this snapshot. The page link may show a newer release later.	USD 15,415 Exact value Exact value: 15415 USD 2017-10-01 – 2018-09-30: 15415 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arch Therapeutics, Inc. · 2018-09-30 Arch Therapeutics, Inc. (edgar:1537561) Capital Expenditure: 15415 USD Concept: fundies:CapitalExpenditure Period: 2017-10-01 to 2018-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ACapitalExpenditure&period=2018-09-30&surface=latest&period_type=duration&start=2017-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 15415 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420418065134/arth-20180930.xml#1227105 Filing: 000114420418065134 The citation records this snapshot. The page link may show a newer release later.	−USD 5.93 million Calculation and evidence -5913563 − 15415 USD Exact free cash flow: -5928978 USD 2017-10-01 – 2018-09-30: -5913563 USD · Inspect Operating Cash Flow · Source 2017-10-01 – 2018-09-30: 15415 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arch Therapeutics, Inc. · 2018-09-30 Arch Therapeutics, Inc. (edgar:1537561) Free cash flow: -5928978 USD Concept: free-cash-flow Period: 2017-10-01 to 2018-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5913563 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420418065134/arth-20180930.xml#1221971 Filing: 000114420418065134 Input fundies:CapitalExpenditure: 15415 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000114420418065134/arth-20180930.xml#1227105 Filing: 000114420418065134 The citation records this snapshot. The page link may show a newer release later.
2020 2019-10-01 – 2020-09-30	−USD 4.69 million Exact value Exact value: -4691377 USD 2019-10-01 – 2020-09-30: -4691377 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arch Therapeutics, Inc. · 2020-09-30 Arch Therapeutics, Inc. (edgar:1537561) Net Income: -4691377 USD Concept: fundies:NetIncome Period: 2019-10-01 to 2020-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ANetIncome&period=2020-09-30&surface=latest&period_type=duration&start=2019-10-01&unit=USD&dimensions= Input fundies:NetIncome: -4691377 USD (2019-10-01 to 2020-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000185173422000639/arch20221021_s1.htm#1611906 Filing: 000185173422000639 The citation records this snapshot. The page link may show a newer release later.	−USD 5.04 million Exact value Exact value: -5044755 USD 2019-10-01 – 2020-09-30: -5044755 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arch Therapeutics, Inc. · 2020-09-30 Arch Therapeutics, Inc. (edgar:1537561) Operating Cash Flow: -5044755 USD Concept: fundies:OperatingCashFlow Period: 2019-10-01 to 2020-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3AOperatingCashFlow&period=2020-09-30&surface=latest&period_type=duration&start=2019-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5044755 USD (2019-10-01 to 2020-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000185173422000639/arch20221021_s1.htm#1632998 Filing: 000185173422000639 The citation records this snapshot. The page link may show a newer release later.	USD 2,455 Exact value Exact value: 2455 USD 2019-10-01 – 2020-09-30: 2455 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arch Therapeutics, Inc. · 2020-09-30 Arch Therapeutics, Inc. (edgar:1537561) Capital Expenditure: 2455 USD Concept: fundies:CapitalExpenditure Period: 2019-10-01 to 2020-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ACapitalExpenditure&period=2020-09-30&surface=latest&period_type=duration&start=2019-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2455 USD (2019-10-01 to 2020-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000185173422000639/arch20221021_s1.htm#1635942 Filing: 000185173422000639 The citation records this snapshot. The page link may show a newer release later.	−USD 5.05 million Calculation and evidence -5044755 − 2455 USD Exact free cash flow: -5047210 USD 2019-10-01 – 2020-09-30: -5044755 USD · Inspect Operating Cash Flow · Source 2019-10-01 – 2020-09-30: 2455 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arch Therapeutics, Inc. · 2020-09-30 Arch Therapeutics, Inc. (edgar:1537561) Free cash flow: -5047210 USD Concept: free-cash-flow Period: 2019-10-01 to 2020-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5044755 USD (2019-10-01 to 2020-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000185173422000639/arch20221021_s1.htm#1632998 Filing: 000185173422000639 Input fundies:CapitalExpenditure: 2455 USD (2019-10-01 to 2020-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000185173422000639/arch20221021_s1.htm#1635942 Filing: 000185173422000639 The citation records this snapshot. The page link may show a newer release later.
2021 2020-10-01 – 2021-09-30	−USD 6.24 million Exact value Exact value: -6240482 USD 2020-10-01 – 2021-09-30: -6240482 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arch Therapeutics, Inc. · 2021-09-30 Arch Therapeutics, Inc. (edgar:1537561) Net Income: -6240482 USD Concept: fundies:NetIncome Period: 2020-10-01 to 2021-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ANetIncome&period=2021-09-30&surface=latest&period_type=duration&start=2020-10-01&unit=USD&dimensions= Input fundies:NetIncome: -6240482 USD (2020-10-01 to 2021-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000185173422000752/arch20220930_10k.htm#1671410 Filing: 000185173422000752 The citation records this snapshot. The page link may show a newer release later.	−USD 5.96 million Exact value Exact value: -5958628 USD 2020-10-01 – 2021-09-30: -5958628 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arch Therapeutics, Inc. · 2021-09-30 Arch Therapeutics, Inc. (edgar:1537561) Operating Cash Flow: -5958628 USD Concept: fundies:OperatingCashFlow Period: 2020-10-01 to 2021-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3AOperatingCashFlow&period=2021-09-30&surface=latest&period_type=duration&start=2020-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5958628 USD (2020-10-01 to 2021-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000185173422000752/arch20220930_10k.htm#1694781 Filing: 000185173422000752 The citation records this snapshot. The page link may show a newer release later.	USD 3,275 Exact value Exact value: 3275 USD 2020-10-01 – 2021-09-30: 3275 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arch Therapeutics, Inc. · 2021-09-30 Arch Therapeutics, Inc. (edgar:1537561) Capital Expenditure: 3275 USD Concept: fundies:CapitalExpenditure Period: 2020-10-01 to 2021-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ACapitalExpenditure&period=2021-09-30&surface=latest&period_type=duration&start=2020-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3275 USD (2020-10-01 to 2021-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000185173422000752/arch20220930_10k.htm#1697778 Filing: 000185173422000752 The citation records this snapshot. The page link may show a newer release later.	−USD 5.96 million Calculation and evidence -5958628 − 3275 USD Exact free cash flow: -5961903 USD 2020-10-01 – 2021-09-30: -5958628 USD · Inspect Operating Cash Flow · Source 2020-10-01 – 2021-09-30: 3275 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arch Therapeutics, Inc. · 2021-09-30 Arch Therapeutics, Inc. (edgar:1537561) Free cash flow: -5961903 USD Concept: free-cash-flow Period: 2020-10-01 to 2021-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5958628 USD (2020-10-01 to 2021-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000185173422000752/arch20220930_10k.htm#1694781 Filing: 000185173422000752 Input fundies:CapitalExpenditure: 3275 USD (2020-10-01 to 2021-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000185173422000752/arch20220930_10k.htm#1697778 Filing: 000185173422000752 The citation records this snapshot. The page link may show a newer release later.
2022 2021-10-01 – 2022-09-30	−USD 5.28 million Exact value Exact value: -5275854 USD 2021-10-01 – 2022-09-30: -5275854 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arch Therapeutics, Inc. · 2022-09-30 Arch Therapeutics, Inc. (edgar:1537561) Net Income: -5275854 USD Concept: fundies:NetIncome Period: 2021-10-01 to 2022-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ANetIncome&period=2022-09-30&surface=latest&period_type=duration&start=2021-10-01&unit=USD&dimensions= Input fundies:NetIncome: -5275854 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2059214 Filing: 000143774924004234 The citation records this snapshot. The page link may show a newer release later.	−USD 4.46 million Exact value Exact value: -4456075 USD 2021-10-01 – 2022-09-30: -4456075 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arch Therapeutics, Inc. · 2022-09-30 Arch Therapeutics, Inc. (edgar:1537561) Operating Cash Flow: -4456075 USD Concept: fundies:OperatingCashFlow Period: 2021-10-01 to 2022-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3AOperatingCashFlow&period=2022-09-30&surface=latest&period_type=duration&start=2021-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4456075 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2081495 Filing: 000143774924004234 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: -0 USD 2021-10-01 – 2022-09-30: -0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arch Therapeutics, Inc. · 2022-09-30 Arch Therapeutics, Inc. (edgar:1537561) Capital Expenditure: -0 USD Concept: fundies:CapitalExpenditure Period: 2021-10-01 to 2022-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ACapitalExpenditure&period=2022-09-30&surface=latest&period_type=duration&start=2021-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: -0 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2084779 Filing: 000143774924004234 The citation records this snapshot. The page link may show a newer release later.	−USD 4.46 million Calculation and evidence -4456075 − -0 USD Exact free cash flow: -4456075 USD 2021-10-01 – 2022-09-30: -4456075 USD · Inspect Operating Cash Flow · Source 2021-10-01 – 2022-09-30: -0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arch Therapeutics, Inc. · 2022-09-30 Arch Therapeutics, Inc. (edgar:1537561) Free cash flow: -4456075 USD Concept: free-cash-flow Period: 2021-10-01 to 2022-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4456075 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2081495 Filing: 000143774924004234 Input fundies:CapitalExpenditure: -0 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2084779 Filing: 000143774924004234 The citation records this snapshot. The page link may show a newer release later.
2023 2022-10-01 – 2023-09-30	−USD 6.98 million Exact value Exact value: -6982836 USD 2022-10-01 – 2023-09-30: -6982836 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arch Therapeutics, Inc. · 2023-09-30 Arch Therapeutics, Inc. (edgar:1537561) Net Income: -6982836 USD Concept: fundies:NetIncome Period: 2022-10-01 to 2023-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ANetIncome&period=2023-09-30&surface=latest&period_type=duration&start=2022-10-01&unit=USD&dimensions= Input fundies:NetIncome: -6982836 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2129531 Filing: 000143774924004234 The citation records this snapshot. The page link may show a newer release later.	−USD 3.37 million Exact value Exact value: -3374216 USD 2022-10-01 – 2023-09-30: -3374216 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arch Therapeutics, Inc. · 2023-09-30 Arch Therapeutics, Inc. (edgar:1537561) Operating Cash Flow: -3374216 USD Concept: fundies:OperatingCashFlow Period: 2022-10-01 to 2023-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3AOperatingCashFlow&period=2023-09-30&surface=latest&period_type=duration&start=2022-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3374216 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2129757 Filing: 000143774924004234 The citation records this snapshot. The page link may show a newer release later.	USD 4,521 Exact value Exact value: 4521 USD 2022-10-01 – 2023-09-30: 4521 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arch Therapeutics, Inc. · 2023-09-30 Arch Therapeutics, Inc. (edgar:1537561) Capital Expenditure: 4521 USD Concept: fundies:CapitalExpenditure Period: 2022-10-01 to 2023-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561/explain?concept=fundies%3ACapitalExpenditure&period=2023-09-30&surface=latest&period_type=duration&start=2022-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4521 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2083940 Filing: 000143774924004234 The citation records this snapshot. The page link may show a newer release later.	−USD 3.38 million Calculation and evidence -3374216 − 4521 USD Exact free cash flow: -3378737 USD 2022-10-01 – 2023-09-30: -3374216 USD · Inspect Operating Cash Flow · Source 2022-10-01 – 2023-09-30: 4521 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arch Therapeutics, Inc. · 2023-09-30 Arch Therapeutics, Inc. (edgar:1537561) Free cash flow: -3378737 USD Concept: free-cash-flow Period: 2022-10-01 to 2023-09-30 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1537561?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3374216 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2129757 Filing: 000143774924004234 Input fundies:CapitalExpenditure: 4521 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1537561/000143774924004234/arch20230930_10k.htm#2083940 Filing: 000143774924004234 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

67 filings · 2,906 latest values · 2,906 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001537561, 1537561, ARTH, aahc, edgar:1537561

Also known as ALMAH,INC, ARCH THERAPEUTICS, INC., Arch Therapeutics, Inc.

Arch Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2023 2022-10-01 – 2023-09-30

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation